{"entity":{"id":"nct06995677","kind":"trial","name":"Efficacy and Safety of TYRA-300 in Participants With FGFR3 Altered Low Grade, Intermediate Risk Non-Muscle Invasive Bladder Cancer","aka":[],"tldr":"A phase 2 trial of TYRA-300 in bladder & urothelial cancer, run by Tyra Biosciences, Inc, now recruiting.","summary":"Efficacy and Safety of TYRA-300 in Participants With FGFR3 Altered Low Grade, Intermediate Risk Non-Muscle Invasive Bladder Cancer is a phase 2 interventional study registered as NCT06995677 by Tyra Biosciences, Inc, with 90 participants planned, started 2025-06-27 and due to reach its primary completion in 2028-02. Interventions recorded: TYRA-300 60mg, TYRA-300 50mg and TYRA-300 Dose TBD.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT06995677","url":"https://clinicaltrials.gov/study/NCT06995677"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["urothelial"],"sections":[],"technologies":[],"targets":[],"drugs":["tyra-300"],"companies":["tyra-biosciences"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT06995677","phase":"2","setting":"A Phase 2 Multicenter, Open-Label Study Evaluating the Efficacy and Safety of TYRA-300 in Participants With FGFR3 Altered Low Grade, Intermediate Risk Non-Muscle Invasive Bladder Cancer (SURF302)","sponsor":"Tyra Biosciences, Inc","enrolled":90,"outcomes":[]},"route":"/trials/nct06995677/","neighbours":{"cancer":[{"id":"urothelial","kind":"cancer","name":"Bladder & urothelial cancer","route":"/cancers/urothelial/"}],"drug":[{"id":"tyra-300","kind":"drug","name":"TYRA-300","route":"/drugs/tyra-300/"}],"company":[{"id":"tyra-biosciences","kind":"company","name":"Tyra Biosciences","route":"/companies/tyra-biosciences/"}]}}